Bionano Genomics Operating Margin vs. Cash Per Share

BNGO Stock  USD 0.26  0.02  8.33%   
Based on Bionano Genomics' profitability indicators, Bionano Genomics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Bionano Genomics' ability to earn profits and add value for shareholders.

Bionano Genomics Operating Profit Margin

(6.26)

At this time, Bionano Genomics' Days Sales Outstanding is very stable compared to the past year. As of the 29th of November 2024, Sales General And Administrative To Revenue is likely to grow to 1.67, while Price To Sales Ratio is likely to drop 1.70. At this time, Bionano Genomics' Accumulated Other Comprehensive Income is very stable compared to the past year. As of the 29th of November 2024, Interest Income is likely to grow to about 3.5 M, while Net Interest Income is likely to drop (1.9 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.340.2649
Significantly Up
Slightly volatile
For Bionano Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bionano Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bionano Genomics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bionano Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bionano Genomics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.30)
Revenue Per Share
0.749
Quarterly Revenue Growth
(0.10)
Return On Assets
(0.33)
Return On Equity
(1.38)
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bionano Genomics Cash Per Share vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bionano Genomics's current stock value. Our valuation model uses many indicators to compare Bionano Genomics value to that of its competitors to determine the firm's financial worth.
Bionano Genomics is rated below average in operating margin category among its peers. It also is rated below average in cash per share category among its peers . At this time, Bionano Genomics' Operating Profit Margin is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bionano Genomics' earnings, one of the primary drivers of an investment's value.

Bionano Cash Per Share vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Bionano Genomics

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
(2.03) %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Bionano Genomics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
0.65 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Bionano Cash Per Share Comparison

Bionano Genomics is currently under evaluation in cash per share category among its peers.

Bionano Genomics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bionano Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bionano Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Bionano Genomics' change in net profit over the period of time. It can combine multiple indicators of Bionano Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income23 K24.1 K
Net Interest Income-1.8 M-1.9 M
Interest Income3.3 M3.5 M
Operating Income-215.2 M-204.5 M
Net Loss-232.5 M-220.9 M
Income Before Tax-232.4 M-220.8 M
Total Other Income Expense Net-17.2 M-16.3 M
Net Loss-119.3 M-113.4 M
Net Loss-232.5 M-220.9 M
Income Tax Expense62 K65.1 K
Non Operating Income Net Other-200.7 K-190.7 K
Change To Netincome29 M30.4 M
Net Loss(6.81)(7.15)
Income Quality 0.54  1.05 
Net Income Per E B T 1.00  1.09 

Bionano Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bionano Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bionano Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bionano Genomics' important profitability drivers and their relationship over time.

Use Bionano Genomics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.

Bionano Genomics Pair Trading

Bionano Genomics Pair Trading Analysis

The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Bionano Genomics position

In addition to having Bionano Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Housewares Thematic Idea Now

Housewares
Housewares Theme
Companies making housewares accessories and providing houseware services. The Housewares theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Housewares Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:
Check out Trending Equities.
To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
To fully project Bionano Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bionano Genomics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bionano Genomics' income statement, its balance sheet, and the statement of cash flows.
Potential Bionano Genomics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Bionano Genomics investors may work on each financial statement separately, they are all related. The changes in Bionano Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bionano Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.